TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Incidence of symptomatic hypogonadism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of eosinophils per high power field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction of the initial HAM-D by 50% or more at week 9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of the HAM-D score to less than or equal to 7 at week 9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of CGI score achievement to very much improved or much improved at week 9
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: A 50% decrease in the GCS at week 9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of individuals with CD4≥250 cells/mm3 and VL≥50,000 cp/mL who start 3-drug ART
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients experiencing Grade 3 or 4 clinical or laboratory adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants with excellent adherence to antiretrovirals
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in systemic vascular resistance (dynes/sec*cm-5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Self-reported Walking for Errands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accelerometer Measured Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking and Cycling Facilities in Neighborhood
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sensory and motor block quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Executive functions: mental flexibility performances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Executive functions: processing speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social cognition: facial emotion recognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-completed Leeds Assessment of Neuropathic Symptoms and Signs pain scale (S-LANSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain level on Verbal Analogue Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUROC of the prediction algorithm for identifying fast progressing myopes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tolerance to α1-AR blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Infant lung development measured by diffusion lung capacity (DLCO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: sudden death elucidation rate
Endpoint domain: Mortality/survival
Primary endpoint: HPV-Specific T Cell Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: fMRI brain responses during inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: fMRI brain response during inhibition to a food stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: fMRI neural network during inhibition to a food stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants who experienced a Dose-Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Distance from probe tube to eardrum measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedure time of fitting workflow including Real Ear measurement
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 1-year adverse evolution
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative bile leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Post operative biliary stricture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Recurrent biliary stones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: weight-status improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of quality signals obtained
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive characteristics of the algorithm for respiratory tract infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero until the time corresponding with the last observed quantifiable concentration (AUC0-t) ratio between tablet formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to infinity (AUC0-∞) ratio between tablet formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) ratio between tablet formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe hypoglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Opioid relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Patients With Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of congenital heart defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Caregiver social support
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change of Peritoneal Equilibration test profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NRS during IUD insertion
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with improvements in Juvenile Rheumatoid Arthritis core set criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean dose required to increase the SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportions of subjects experiencing treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in performance on the orthopedic basic competency exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Brain Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain structural and functional change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Disease resolution percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Clinical Endpoint (CCE) for Clinical Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coefficient of correlation between biliary concentration of TCR and PBMC concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV reservoirs measured by HIV DNA distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: LDL-cholesterolemia absolute reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LDL-cholesterolemia % reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to repeat arrest for driving under the influence of alcohol
Endpoint domain: Mortality/survival
Primary endpoint: Low Density Lipoprotein-cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Length of stay in emergency department
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Stunting based on Anthropometric Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight-for-Height based on Anthropometric Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Raven's Colored Progressive Matrices test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Successful Kidney Transplantation From a Cross-match Compatible Donor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants With Verified HRS Reversal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Were Viable (Per Protocol) for Inclusion in the Primary End Point Analysis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Differentially expressed microRNAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Node-positive disease following surgical resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: muscle force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: muscle power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in percent free and total serum prostate-specific antigen (PSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall rating of intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Would recommend intervention to others
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of discharge teaching
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: disease free survival at six months
Endpoint domain: Mortality/survival
Primary endpoint: Readmissions Days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Osseous volumetric fill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: use of rFVIIa in haemorrhagic trauma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of achieving >5% weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Subjects Achieving Greater Than or Equal to 10% Total Body Weight Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Children's physical activity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychometric Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients cured on day 28
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients who tolerate abatacept
Endpoint domain: Adverse events/effects
Primary endpoint: Initiation of provider visit for prostate cancer screening
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: change in physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Average Threshold Shift at 4 kHz in Both Ears
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average bloating scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frost Multidimensional Perfectionism Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Complete Clearance of Disease at Week 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return to BNI O.R. for wound washout
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Treatment Emergent Adverse Events (AEs) by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptance of testing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Return for test results
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Intention to access health services
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: length of the cervix in mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: BOLD (blood oxygen level-dependent) activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breast health status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute difference to baseline in concentrations of C-reactive Protein (CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Wrinkle Severity Rating Scale (WSRS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Image quality assessed by standardized uptake values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biodistribution of [18F]3F-PHPG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DNA Methylation Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor response according to Cheson criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Blood counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: incidence of ovarian cyst
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Movement Imagination Questionnaire - Revised Second
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Task Completion Time
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Attrition rate due to any adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of lower extremity lymphedema symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Absorbed Radiation Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of micturations and incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in the level of state anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients achieving ≥ 85% of planned dose intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with ≥ 1 neutropenic event
Endpoint domain: Adverse events/effects
Primary endpoint: VO2 Peak Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Heart Rate Variability (HRV; RMSSD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Distinction between radiation necrosis and progressive tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single muscle fiber structure/function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of ED presentations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Successful sand fly bite exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Zarit Burden Interview - Change from Baseline
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Center for Epidemiologic Studies Depression Scale - Change from Baseline
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Short Form - VR 12 Health Survey - Change from Baseline
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Evaluation of Growth: Height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of Growth: Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of Growth: Body Mass Index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sexual Maturity Based on the Tanner scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores on causal tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to 25% decrease in chromogranin A plasma level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSWQ (Penn State Worry Questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: STAI-T (State-Trait Anxiety Inventory - Trait)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Completion of foot exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Growth Rate (cm/Year)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Growth Rate (SD Units)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of All Treatment Related Adverse Events (TRAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Degree of Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Investigator's Assessment of Clinical Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with grade 2 or 3 fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating tissue factor bearing microparticles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Objective Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate in Cohort 1 (AML)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response rate in Cohort 2 (other myeloid neoplasms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Self-reported prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PRA and aldosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time to wean
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inflammation of soft tissue and bony elements of the middle turbinate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects with Local and Systemic Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects Who Developed Titers of ≥1:40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: EtCO2 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: compression index of left ventricle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: compression index of right ventricle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: compression index of inferior caval vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of EMT and acute care events
Endpoint domain: Adverse events/effects
Primary endpoint: Placental Microvascular Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to diagnosis and treatment for extremity fractures or dislocations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Treatment Success (Complete Clearance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ethical decision-making clinical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of cardiac death, myocardial infarction (MI) and stent thrombosis
Endpoint domain: Mortality/survival
Primary endpoint: t½,ss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early detection of renal injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pathologic complete regression (pCR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Freedom from the composite SoundBite™ Crossing System related MAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects that do not experience death following delivery of shockwave energy
Endpoint domain: Mortality/survival
Primary endpoint: Number of subjects without any procedure and/or device related adverse events (30 days)
Endpoint domain: Adverse events/effects
Primary endpoint: Acute technical success of the device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Effectiveness of paracervical block vs Lidocaine spray
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pain management outcomes
Primary endpoint: uptake of 111Indium-CHX-A DTPA trastuzumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Combined Score (TCS) During the Peak Ragweed Season
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in acneiform eruption
Endpoint domain: Adverse events/effects
Primary endpoint: Post-vaccination HI antibody titre
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: onset of antidepressant efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in glycated hemoglobin (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes